Clinical trials: Metastatic Neoplasm
Metastatic Melanoma, Advanced Locoregional Melanoma
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
Background: Aldesleukin is used to treat metastatic or advanced melanoma and renal cell carcinoma. Pembrolizumab is used to treat many cancers including melanoma.
- Conditions
- Metastatic Melanoma, Advanced Locoregional Melanoma, Metastatic Renal Cell Carcinoma, Clear Cell Histology
- Trial name
- NCT05155033
- Testing
- Pembrolizumab, Aldesleukin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer Metastatic, Skin Toxicity
Pre-emptive Cycline Treatment on Cetuximab Induced Skin Toxicity in Colorectal Cancer
The aim of this study is to test the role of cycline in the prevention of acne-like skin rash in metastatic colorectal patients treated with Cetuximab and intensified FOLFIRI.
- Trial name
- SKINUX (NCT01317433)
- Testing
- Doxycycline, Cetuximab
- Where
- 5 sites in France
- Volunteers
- 25 people
- Sponsor
- Institut Cancerologie de l'Ouest
Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer
ACP-196 Alone and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Pancreatic Cancer
- Trial name
- KEYNOTE144 (NCT02362048)
- Testing
- ACP-196, ACP-196 in combination with pembrolizumab
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- Acerta Pharma BV
Advanced Non-Hematologic Malignancies
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
Dose finding study of the MoaB PF-04605412 directed against the alpha5beta1 integrin. Main objective is to define the MTD (maximum tolerated dose) or MAD (maximum administrable dose) in cancer patients pre treated or unresponsive…
- Trial name
- NCT00915278
- Testing
- PF-04605412
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 33 people
- Sponsor
- Pfizer
Unresectable Hepatocellular Carcinoma (HCC), Liver Metastases From Colorectal Cancer (mCRC)
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)
This registry seeks to prospectively gather a large repository of comprehensive observational data reflecting routine use of SIR-Spheres in patients diagnosed with unresectable HCC or unresectable liver metastases from mCRC…
- Trial name
- SIRtain (NCT05967143)
- Testing
- SIRT
- Where
- 9 sites in France, Spain and 1 more
- Volunteers
- 845 people
- Sponsor
- Sirtex Medical
Metastatic Cancer, Prostate Cancer
Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008
RATIONALE: Drugs used in chemotherapy such as docetaxel work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00084825
- Testing
- Docetaxel, Imatinib mesylate
- Where
- 3 sites in United States
- Volunteers
- 23 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Metastatic Cancer
Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer
This is an open-label, single-center, single-arm phase II clinical trial evaluating the combination of pembrolizumab, binimetinib, and bevacizumab in patients with metastatic colorectal adenocarcinoma who have not responded to…
- Trial name
- NCT03475004
- Testing
- Pembrolizumab, Bevacizumab, Binimetinib
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cognitive/Functional Effects, Metastatic Cancer
Memantine in Preventing Side Effects in Patients Undergoing Whole-Brain Radiation Therapy for Brain Metastases From Solid Tumors
RATIONALE: Memantine may be able to decrease side effects caused by whole-brain radiation therapy. It is not yet known if memantine is effective in preventing side effects caused by whole-brain radiation therapy.
- Conditions
- Cognitive/Functional Effects, Metastatic Cancer, Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00566852
- Testing
- Memantine, Whole brain radiation therapy
- Where
- 235 sites in United States, Canada
- Volunteers
- 554 people
- Sponsor
- Radiation Therapy Oncology Group
Metastases, Neoplasm
Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases
Published prognostic scores have limitations in prediction of long term survival after stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available for prediction of local failure.
- Trial name
- NCT02265549
- Where
- Netherlands
- Volunteers
- 155 people
- Sponsor
- Maastricht Radiation Oncology
Bladder Cancer, URINARY BLADDER
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Standard chemotherapy drugs generally work by killing rapidly dividing cells in your body. Cancers cells are some of the most rapidly dividing cells and that is why chemotherapy can be effective in some patients.
- Trial name
- NCT00714948
- Testing
- gemcitabine and cisplatin plus sorafenib
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatic Metastasis of Colorectal Cancer
Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer
To evaluate the safety of karillizumab combined with apatinib mesylate, XELOX and radiofrequency ablation
- Trial name
- NCT04202978
- Testing
- Camrelizumab, Apatinib Mesylate, Capecitabine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Zhongshan Hospital Xiamen University
Lung Cancer, Non-Small Cell
A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer
This study was designed to evaluate and compare the efficacy of two dose schedules of an oral investigational drug for the treatment of advanced or metastatic non-small cell lung cancer.
- Trial name
- NCT00073008
- Testing
- GW572016 (lapatinib)
- Where
- 31 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms, Breast Cancer, Metastatic
Evaluation of BAY59-8862 in Taxane-Resistant Metastatic Breast Cancer Patients
Breast cancer is the most common form of cancer among women in developing countries, accounting for approximately one-fifth of all female cancers in the United States.
- Trial name
- NCT00044525
- Testing
- BAY59-8862 (Cytotoxic Taxane)
- Where
- 22 sites in Germany, Greece and 5 more
- Volunteers
- 82 people
- Sponsor
- Bayer
Metastatic Cancer
Implementing Precision Medicine in cOmmunity HospiTALs
This is a prospective biomarker study that aims at demonstrating the impact of liquid biopsy to deliver better treatment for cancer patients with metastatic disease managed in the community setting
- Trial name
- PRISM-POrTAL (NCT05283044)
- Testing
- biopsy liquid
- Where
- 21 sites in France, French Polynesia and 1 more
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Cancer
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
This was a Phase II, multicenter, non-randomized, open-label study to assess the efficacy, safety, and tolerability of dabrafenib administered as a single agent and in combination with trametinib in stage IV disease to subjects…
- Trial name
- NCT01336634
- Testing
- Dabrafenib, Trametinib
- Where
- 50 sites in United States, France and 9 more
- Volunteers
- 177 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Neoplasms
Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
Investigating the efficacy of maintenance and reinduction treatment or no treatment and watchful waiting in subjects with inoperable or irresectable and non-progressive metastatic colorectal cancer after first line induction…
- Trial name
- NCT00973609
- Testing
- 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab
- Where
- Germany
- Volunteers
- 853 people
- Sponsor
- AIO-Studien-gGmbH
Locally Advanced or Metastatic Urothelial Carcinoma
A Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma
The study is being conducted to evaluate the efficacy and safety of Toripalimab Injection in combination with chemotherapy compared to placebo in combination with chemotherapy in subjects with PD-L1-positive unresectable locally…
- Trial name
- NCT04568304
- Testing
- Toripalimab Injection, Gemcitabine Hydrochloride for Injection, Cisplatin for Injection / Carboplatin Injection
- Where
- 3 sites in China
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Metastatic Breast Cancer
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period
PALBO is a Non-Interventional, National Study Of Real-World Evidence In Estrogen Receptor Positive, Her2 Negative Metastatic Breast Cancer Patients Treated With Palbociclib During A 2.5 Years Follow-Up Period.
- Trial name
- PALBO (NCT05135104)
- Testing
- Palbociclib
- Where
- 7 sites in Romania
- Volunteers
- 650 people
- Sponsor
- Asociatia Oncohelp - Centrul de Oncologie Oncohelp
Colorectal Cancer
Phase I/II Study of SOL for Untreated Metastatic Colorectal Cancer
Introduction: S-1 is promising drug which could replace 5-fluorouracil plus l-leucovorin (5-FU/l-LV) in treatment of advanced colorectal cancer.
- Trial name
- NCT00524706
- Testing
- S-1, oral Leucovorin, Oxaliplatin
- Where
- Japan
- Volunteers
- 42 people
- Sponsor
- Shizuoka Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.